Themis Biosciences Signs an Exclusive License Agreement with Max-Planck-Innovation for Oncolytic Virotherapies

 Themis Biosciences Signs an Exclusive License Agreement with Max-Planck-Innovation for Oncolytic Virotherapies

Themis Biosciences Signs an Exclusive License Agreement with Max-Planck-Innovation for Oncolytic Virotherapies

Shots:

  • Themis to get global rights to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform, collaborately developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry
  • The agreement focus on expanding immunomodulation portfolio for developing multiple immuno-oncology therapeutics
  • The licensed technology is based on the viral genome sequence of the measles vaccine strain used to immunize globally and can also be used for killing tumor cells

Click here to read full press release/ article | Ref: Themis Biosciences| Image: Themis Biosciences

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post